Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949085 | 0.88 | SLC6A9 (0.67) | SLC6A9CYP2C9 | |
| SCHEMBL14686257 | 0.88 | SLC6A9 (0.73) | SLC6A9CYP2C9 | |
| SCHEMBL3541212 | 0.87 | SLC6A9 (0.75) | SLC6A9CYP2C9 | |
| SCHEMBL3542293 | 0.87 | SLC6A9 (0.72) | SLC6A9CYP2C9 | |
| SCHEMBL27684011 | 0.86 | SLC6A9 (0.53) | SLC6A9CYP2C9 | |
| SCHEMBL3049313 | 0.84 | SLC6A9 (0.67) | SLC6A9CYP2C9 | |
| SCHEMBL3651485 | 0.84 | SLC6A9 (0.70) | SLC6A9CYP2C9 | |
| SCHEMBL3540629 | 0.84 | SLC6A9 (0.67) | SLC6A9CYP2C9 | |
| SCHEMBL3042378 | 0.83 | SLC6A9 (0.66) | SLC6A9CYP2C9 | |
| SCHEMBL3061373 | 0.83 | SLC6A9 (0.66) | SLC6A9CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831201-B1 | PIPERIDINE AND AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-7655644-B2 | Piperidine and azetidine derivatives as GlyT1 inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-20080090796-A1 | Piperidine And Azetidine Derivatives As Glyt1 Inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090796-A1 | Piperidine And Azetidine Derivatives As Glyt1 Inhibitors | SLC6A7, SLC1A1, SLC1A2 | SLC6A9 11/4885CYP2C9 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.